Principal Financial Group
EIDX

Principal Financial Group’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

Principal Financial Group’s Portfolio EIDX Stock Details EIDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-2,771
Closed -$365K – 2528
2020
Q4 		$365K Sell
2,771
-5,130
-65% -$453K ﹤0.01% 2197
2020
Q3 		$399K Sell
7,901
-106
-1% -$4.76K ﹤0.01% 2062
2020
Q2 		$382K Buy
8,007
+2,413
+43% +$112K ﹤0.01% 2036
2020
Q1 		$274K Buy
5,594
+181
+3% +$9.22K ﹤0.01% 1983
2019
Q4 		$311K Buy
+5,413
New +$268K ﹤0.01% 2048

Principal Financial Group's EIDX Position: Q1 2021 in Review

Principal Financial Group sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q1 2021, closing a stake of 2,771 shares — an estimated $365K sold.

Principal Financial Group first reported a position in EIDX in Q4 2019 and held it in 5 quarters. The position peaked at $399K in Q3 2020. 0 funds tracked by Wall St. Rank hold EIDX as of Q1 2021.

  • Principal Financial Group reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Principal Financial Group sold 2,771 Eidos Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $365K.
  • Principal Financial Group first reported a position in Eidos Therapeutics, Inc. Common Stock in Q4 2019 and held it in 5 quarters.
  • Principal Financial Group's Eidos Therapeutics, Inc. Common Stock position peaked at $399K in Q3 2020.
  • 0 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q1 2021.

Based on Principal Financial Group's 13F filing for Q1 2021, filed 10 May 2021.